Qiangwei Liang
Overview
Explore the profile of Qiangwei Liang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Liang Q, Cao Y, Yang T, An M, Liu Z, et al.
J Nanobiotechnology
. 2024 Jun;
22(1):319.
PMID: 38849938
Myeloid-derived suppressor cells (MDSCs) have played a significant role in facilitating tumor immune escape and inducing an immunosuppressive tumor microenvironment. Eliminating MDSCs and tumor cells remains a major challenge in...
2.
Cao Y, Li J, Liang Q, Yang J, Zhang X, Zhang J, et al.
ACS Appl Mater Interfaces
. 2023 Nov;
15(47):54898-54914.
PMID: 37963093
The antitumor immune response of cancer immunotherapy is a cascade of cancer-immunity cycles (CIC). The immunosuppression of the tumor microenvironment and low immunogenicity of tumor cells, insufficient T lymphocyte activation,...
3.
Zhou L, Liang Q, Li Y, Cao Y, Li J, Yang J, et al.
Acta Biomater
. 2022 Sep;
152:235-254.
PMID: 36087869
Liver fibrosis is a pathological process of multiple chronic liver diseases progressing to cirrhosis for which there are currently no effective treatment options. During fibrosis progression, the overproduction of extracellular...
4.
Li Y, Liang Q, Zhou L, Cao Y, Yang J, Li J, et al.
Acta Biomater
. 2022 Sep;
152:406-424.
PMID: 36055613
The signaling cascade between nuclear factor-kappa B (NF-κB) and hypoxia-inducible factor-1α (HIF-1α) can be activated by proinflammatory M1 macrophages in rheumatoid arthritis (RA), which produces reactive oxygen species (ROS) and...
5.
Liang Q, Lan Y, Li Y, Cao Y, Li J, Liu Y
Eur J Pharm Biopharm
. 2022 Jul;
177:260-272.
PMID: 35863668
Chemotherapeutic agents can trigger the immune response via inducing immunogenic cell death (ICD), but the weak ICD effect induced by chemotherapy alone limits its lasting antitumor immunotherapy effect. A Cro...
6.
Cao Y, Liang Q, Lan Y, Liu Y
Pharm Dev Technol
. 2022 May;
27(4):469-478.
PMID: 35579888
Nowadays, breast cancer has become a major killer threatening women's health. MET is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor, activates downstream pathways with...
7.
Zhou L, Li Y, Liang Q, Liu J, Liu Y
J Drug Target
. 2022 Feb;
30(6):577-588.
PMID: 35179094
Liver fibrosis is the hallmark of liver disease and occurs prior to the stages of cirrhosis and hepatocellular carcinoma. Any type of liver damage or inflammation can result in fibrosis....
8.
Liang Q, Zhou L, Li Y, Liu J, Liu Y
J Drug Target
. 2021 May;
30(2):119-130.
PMID: 33960252
The abnormal structure and function of blood vessels in the TME are obvious characteristics of the tumour. Abnormal blood vessels with high leakage support the occurrence of malignant tumours and...
9.
Sun Y, Liu L, Zhou L, Yu S, Lan Y, Liang Q, et al.
ACS Appl Mater Interfaces
. 2020 Sep;
12(41):45873-45890.
PMID: 32924511
Cancer metastasis is the leading cause of high mortality and disease recurrence in breast cancer. In this study, a novel tumor microenvironment charge reversal polymetformin (PMet)-based nanosystem co-delivering doxorubicin (DOX)...
10.
Lan Y, Liang Q, Sun Y, Cao A, Liu L, Yu S, et al.
ACS Appl Mater Interfaces
. 2020 Jun;
12(28):31904-31921.
PMID: 32551517
Immunochemotherapy is viewed as a promising approach for cancer therapy combination treatment with immune-modulating drugs and chemotherapeutic drugs. A novel dual-functional immunostimulatory polymeric prodrug carrier PEG-Fmoc-1-MT was developed for simultaneously...